SpliceBio to Attend and Present at Key Scientific and Investor Conferences in April to June 2024
BARCELONA, 10 April 2024 – SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce that its management team will be attending and presenting at key scientific and investor conferences in April to June 2024.
SpliceBio is revolutionizing genetic medicine with its Protein Splicing platform and shaping the gene therapy field with its next generation gene therapies. Following the strengthening of its leadership team with the appointment of leading ophthalmology expert Aniz Girach as Chief Medical Officer in January 2024, SpliceBio is advancing its lead program targeting Stargardt disease towards clinical development with its novel gene therapy modality. Pre-clinical data readouts will be presented at upcoming scientific conferences.
Date: 9-11 April 2024
Presentation title: Company Presentation
Presentation date & time: 10 April, 11:00 – 11:15 CEST
Presenter: Gerard Caelles, Chief Business Officer
Anglonordic Life Science Conference – London, UK
Date: 18 April 2024
Panel title: What Next for Cell & Gene Therapies
Panel presentation date & time: 18 April, 13:45 BST
Panel participation: Miquel Vila-Perelló, Co-founder and Chief Executive Officer
Retinal Cell and Gene Therapy Innovation Summit – Seattle, US
Date: 3 May 2024
Presentation title: Intein-based dual-AAV gene therapy for Stargardt disease
Presentation date & time: 3 May, 09:50 – 10:05 PDT
Presenter: Aniz Girach, Chief Medical Officer
Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting – Seattle, US
Date: 5-9 May 2024
Poster presentation title: Preclinical safety and efficacy of intein-based dual-AAV gene therapy for Stargardt disease
Presentation date & time: 9 May, 08:00 – 09:45 PDT
Presenter: Julian Esteve, Director, Head of Ophthalmology
American Society of Gene and Cell Therapy (ASGCT) – Baltimore, US
Date: 7-11 May 2024
Poster presentation title: Preclinical safety and efficacy of intein-based dual-AAV gene therapy for Stargardt disease
Presentation date & time: 8 May, 12:00 – 19:00 EDT
Attendee: Marianna di Scala, Director, Head of Translation
BioEquity Europe – San Sebastián, Spain
Date: 12-14 May 2024
Presentation title: Company Presentation
Presenter: Miquel Vila-Perelló, Co-founder and Chief Executive Officer
If you would like to meet with the SpliceBio team at any of the above events, please contact us at info@splice.bio. For more information, please visit us at SpliceBio.com.
-Ends-
For further information:
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates
Tel: +44 (0) 20 3882 9621
Email: splicebio@optimumcomms.com
About SpliceBio
SpliceBio is a genetic medicines company harnessing its proprietary Protein Splicing platform to develop the next generation of gene therapies. The Company’s platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by adeno-associated virus (AAV) vectors. The company’s lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. For additional information, please visit www.splice.bio.